When progression-free survival fails to inform: the need for event-level reporting in oligometastatic radiotherapy trials.
Where this comes from
- Record sourced from PubMed, PMID 42686025.
- Also identified by DOI 10.1016/j.radonc.2026.111754.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Progression-free survival treats biologically and clinically distinct progression events equivalently, limiting its interpretability in oligometastatic radiotherapy trials. Across 21 randomized trials, event-level reporting was frequently absent, and none described how post-radiotherapy imaging was adjudicated within PFS. Pragmatic reporting standards could improve interpretation without requiring new endpoints or altered trial design.